Free Trial
Memorial Day Savings! Save $100 on MarketBeat All Access
Claim Your Discount
Claim MarketBeat All Access Sale Promotion

Zimmer Biomet (ZBH) Financials

Zimmer Biomet logo
$85.39 +0.01 (+0.01%)
Closing price 03:59 PM Eastern
Extended Trading
$85.33 -0.06 (-0.07%)
As of 04:47 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
Annual Income Statements for Zimmer Biomet

Annual Income Statements for Zimmer Biomet

This table shows Zimmer Biomet's income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Income / (Loss) Attributable to Common Shareholders
147 306 1,814 -379 1,132 -139 401 230 1,023 902 705
Consolidated Net Income / (Loss)
146 305 1,813 -379 1,132 -137 402 231 1,024 904 705
Net Income / (Loss) Continuing Operations
146 305 1,813 -379 1,132 -9.20 891 291 1,025 905 705
Total Pre-Tax Income
153 400 465 -271 906 -105 499 404 1,067 1,037 831
Total Operating Income
467 821 799 34 1,138 83 860 696 1,278 1,286 1,098
Total Gross Profit
4,197 5,233 5,670 5,661 5,730 4,303 4,867 4,920 5,310 5,487 5,738
Total Revenue
5,998 7,615 7,803 7,933 7,982 6,128 6,827 6,940 7,394 7,679 8,232
Operating Revenue
5,998 7,615 7,803 7,933 7,982 6,128 6,827 6,940 7,394 7,679 8,232
Total Cost of Revenue
1,801 2,382 2,133 2,272 2,253 1,824 1,960 2,020 2,084 2,191 2,494
Operating Cost of Revenue
1,801 2,382 2,133 2,272 2,253 1,824 1,960 2,020 2,084 2,191 2,494
Total Operating Expenses
3,730 4,412 4,871 5,627 4,592 4,220 4,007 4,224 4,033 4,202 4,640
Selling, General & Admin Expense
2,284 2,945 3,105 3,379 3,344 2,713 2,843 2,762 2,839 2,930 3,257
Research & Development Expense
269 366 370 392 449 323 436 406 459 437 459
Amortization Expense
337 566 604 596 584 512 530 527 562 592 666
Other Operating Expenses / (Income)
- - 444 246 95 51 56 34 22 24 77
Restructuring Charge
- 505 18 34 50 119 126 203 152 219 181
Total Other Income / (Expense), net
-314 -422 -335 -305 -232 -188 -361 -293 -211 -249 -267
Interest Expense
287 355 325 289 227 212 374 165 201 218 293
Other Income / (Expense), net
-37 -67 -9.40 -16 -4.80 24 12 -128 -9.30 -31 26
Income Tax Expense
7.00 95 -1,349 108 -226 -96 54 112 42 131 126
Net Income / (Loss) Attributable to Noncontrolling Interest
-0.80 -1.30 -0.40 -0.10 -0.10 1.50 0.50 1.00 1.10 1.50 -0.10
Basic Earnings per Share
$0.78 $1.53 $8.98 ($1.86) $5.52 ($0.67) $1.93 $1.10 $4.91 $4.45 $3.56
Weighted Average Basic Shares Outstanding
187.40M 200M 201.90M 203.50M 205.10M 207M 208.60M 209.60M 208.70M 203.10M 198M
Diluted Earnings per Share
$0.77 $1.51 $8.90 ($1.86) $5.47 ($0.67) $1.91 $1.10 $4.88 $4.43 $3.55
Weighted Average Diluted Shares Outstanding
189.80M 202.40M 203.70M 203.50M 206.70M 207M 210.40M 210.30M 209.70M 203.90M 198.70M
Weighted Average Basic & Diluted Shares Outstanding
188.50M 199.90M 202M 203.90M 206.40M 207.86M 209.18M 208.98M 205.08M 199.06M 195.65M
Cash Dividends to Common per Share
$0.88 $0.96 $0.96 $0.96 $0.96 $0.96 $0.96 $0.96 $0.96 $0.96 $0.96

Quarterly Income Statements for Zimmer Biomet

This table shows Zimmer Biomet's income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
Net Income / (Loss) Attributable to Common Shareholders
163 419 172 243 249 239 181 152 231 141 238
Consolidated Net Income / (Loss)
163 419 172 243 249 239 182 153 231 139 238
Net Income / (Loss) Continuing Operations
163 420 173 243 249 240 183 153 231 138 238
Total Pre-Tax Income
219 285 215 302 230 289 229 225 279 98 301
Total Operating Income
267 354 266 351 280 389 292 300 351 155 373
Total Gross Profit
1,235 1,401 1,377 1,388 1,286 1,437 1,359 1,485 1,442 1,451 1,511
Total Revenue
1,754 1,940 1,889 1,942 1,824 2,023 1,909 2,077 2,001 2,244 2,087
Operating Revenue
1,754 1,940 1,889 1,942 1,824 2,023 1,909 2,077 2,001 2,244 2,087
Total Cost of Revenue
519 539 512 554 539 587 550 592 559 792 576
Operating Cost of Revenue
519 539 512 554 539 587 550 592 559 792 576
Total Operating Expenses
968 1,047 1,111 1,037 1,006 1,047 1,067 1,185 1,091 1,297 1,137
Selling, General & Admin Expense
675 722 736 737 710 747 759 815 811 872 850
Research & Development Expense
117 113 108 109 112 109 111 113 116 119 103
Amortization Expense
145 145 142 144 148 158 151 161 177 178 162
Other Operating Expenses / (Income)
7.30 5.20 0.40 5.20 4.40 14 11 79 -34 22 16
Restructuring Charge
24 61 124 42 32 21 36 18 21 106 6.30
Total Other Income / (Expense), net
-47 -70 -51 -49 -49 -100 -63 -75 -72 -57 -72
Interest Expense
51 50 51 51 54 62 66 79 75 72 69
Other Income / (Expense), net
3.80 -20 -0.10 2.00 5.10 -38 2.90 3.90 3.30 15 -3.00
Income Tax Expense
56 -135 42 59 -19 49 47 71 48 -40 63
Net Income / (Loss) Attributable to Noncontrolling Interest
0.20 0.50 0.40 0.30 0.20 0.60 0.60 0.60 0.30 -1.60 0.20
Basic Earnings per Share
$0.78 $2.02 $0.84 $1.18 $1.23 $1.20 $0.92 $0.77 $1.17 $0.70 $1.22
Weighted Average Basic Shares Outstanding
208.90M 208.70M 205.20M 205.70M 202.30M 203.10M 198.90M 197.90M 198.10M 198M 195M
Diluted Earnings per Share
$0.77 $2.00 $0.84 $1.18 $1.23 $1.18 $0.91 $0.77 $1.16 $0.71 $1.22
Weighted Average Diluted Shares Outstanding
210M 209.70M 206.20M 206.40M 203M 203.90M 199.70M 198.30M 198.80M 198.70M 195.80M
Weighted Average Basic & Diluted Shares Outstanding
208.98M 205.08M 205.73M 203.65M 199.07M 199.06M 197.85M 198.10M 198.18M 195.65M 193.46M
Cash Dividends to Common per Share
$0.24 $0.24 $0.24 $0.24 $0.24 $0.24 $0.24 $0.24 $0.24 - $0.24

Annual Cash Flow Statements for Zimmer Biomet

This table details how cash moves in and out of Zimmer Biomet's business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Change in Cash & Equivalents
376 -825 -110 29 75 169 -324 -103 40 110 66
Net Cash From Operating Activities
850 1,632 1,582 1,747 1,586 1,076 1,404 1,356 1,582 1,499 1,697
Net Cash From Continuing Operating Activities
850 1,632 1,582 1,747 1,586 1,076 1,404 1,356 1,582 1,499 1,697
Net Income / (Loss) Continuing Operations
146 305 1,813 -379 1,132 -9.20 446 291 1,025 905 705
Consolidated Net Income / (Loss)
146 305 1,813 -379 1,132 - - - 1,025 905 705
Depreciation Expense
712 1,039 1,063 1,041 1,006 898 938 926 952 996 1,094
Non-Cash Adjustments To Reconcile Net Income
446 465 418 1,045 154 577 257 514 100 101 90
Changes in Operating Assets and Liabilities, net
-455 -177 -1,712 41 -706 -390 -236 -376 -495 -503 -192
Net Cash From Investing Activities
-7,558 -1,692 -511 -417 -729 -564 -443 -522 -779 -888 -1,976
Net Cash From Continuing Investing Activities
-7,558 -1,692 -511 -417 -729 -564 -443 -522 -779 -888 -1,976
Purchase of Property, Plant & Equipment
-168 -185 -156 -163 -207 -112 -144 -188 -291 -204 -225
Acquisitions
-7,760 -1,443 -4.00 -15 -235 -227 -8.40 -130 -238 -429 -1,446
Sale and/or Maturity of Investments
803 286 - 69 - - 1.90 - 33 22 -0.40
Other Investing Activities, net
-288 -349 -351 -308 -336 -279 -293 -294 -283 -277 -305
Net Cash From Financing Activities
7,107 -743 -1,211 -1,302 -780 -420 -1,306 -776 -764 -485 326
Net Cash From Continuing Financing Activities
7,107 -743 -1,211 -1,302 -780 -420 -1,306 -776 -764 -485 326
Repayment of Debt
-3,320 -2,099 -1,850 -2,984 -1,476 -1,781 -2,674 -1,525 -461 -935 -1,503
Repurchase of Common Equity
-150 -416 - - - 0.00 0.00 -126 -692 -868 -487
Payment of Dividends
-157 -188 -194 -195 -197 -199 -345 -201 -201 -196 -190
Issuance of Debt
10,628 1,824 593 1,825 749 1,497 1,600 458 500 1,436 2,492
Issuance of Common Equity
105 137 146 108 158 130 123 78 101 82 40
Other Financing Activities, net
0.70 0.00 94 -57 -15 -68 -8.90 541 -10 -3.50 -25
Other Net Changes in Cash
- -23 29 - -1.50 78 21 -161 0.90 -17 19

Quarterly Cash Flow Statements for Zimmer Biomet

This table details how cash moves in and out of Zimmer Biomet's business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
Net Change in Cash & Equivalents
-28 124 -23 27 149 -44 859 -828 736 -701 -168
Net Cash From Operating Activities
338 588 228 369 396 506 383 378 419 517 359
Net Cash From Continuing Operating Activities
338 589 228 369 396 506 383 378 419 517 359
Net Income / (Loss) Continuing Operations
163 420 173 243 249 240 183 153 231 138 238
Consolidated Net Income / (Loss)
163 - 173 243 249 - 183 153 231 138 238
Depreciation Expense
241 241 239 243 251 264 254 272 284 284 270
Non-Cash Adjustments To Reconcile Net Income
16 23 29 26 25 21 20 21 25 24 24
Changes in Operating Assets and Liabilities, net
-82 -95 -212 -143 -129 -19 -74 -68 -121 71 -173
Net Cash From Investing Activities
-166 -221 -195 -247 -155 -291 -106 -1,384 -163 -322 -159
Net Cash From Continuing Investing Activities
-166 -221 -195 -247 -155 -291 -106 -1,384 -163 -322 -159
Purchase of Property, Plant & Equipment
-84 -63 -55 -53 -45 -52 -45 -50 -55 -75 -36
Acquisitions
-98 -107 -43 -54 -169 -193 -2.40 -1,256 -10 -177 -39
Sale and/or Maturity of Investments
- - 10 - - - - 2.50 - - -0.30
Other Investing Activities, net
8.80 -57 -107 -147 56 -49 -60 -81 -90 -75 -83
Net Cash From Financing Activities
-196 -251 -50 -92 -102 -241 575 164 484 -897 -369
Net Cash From Continuing Financing Activities
-196 -251 -50 -92 -102 -241 576 164 484 -897 -369
Repayment of Debt
-22 11 -11 -2.00 -57 -816 -894 -2.10 -5.90 -601 -16
Repurchase of Common Equity
- -410 -114 -86 -596 -72 -230 -7.20 - -250 -250
Payment of Dividends
-50 -46 -51 -56 -50 -39 -48 -48 -48 -48 -47
Issuance of Debt
-145 175 70 45 585 686 1,748 220 524 - 0.00
Issuance of Common Equity
21 19 56 6.60 19 0.50 17 0.40 21 1.70 12
Other Financing Activities, net
- - -1.50 - -2.00 - -17 - -7.60 - -69
Other Net Changes in Cash
- 7.40 -5.70 - - - - 15 -3.40 0.80 1.10

Annual Balance Sheets for Zimmer Biomet

This table presents Zimmer Biomet's assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Total Assets
27,161 26,684 26,014 24,127 24,639 24,418 23,456 21,066 21,497 21,365 23,092
Total Current Assets
5,854 4,664 4,565 4,427 4,724 5,083 4,885 4,427 4,610 4,672 5,120
Cash & Equivalents
1,459 634 524 543 618 802 378 376 416 526 592
Accounts Receivable
1,447 1,604 1,544 1,276 1,364 1,453 1,260 1,382 1,442 1,481 1,704
Inventories, net
2,254 1,959 2,068 2,257 2,385 2,451 2,148 2,147 2,385 2,235 2,286
Prepaid Expenses
529 466 428 352 357 169 271 523 366 430 537
Current Deferred & Refundable Income Taxes
- - - - - 209 327 0.00 0.00 0.00 0.00
Plant, Property, & Equipment, net
2,063 2,038 2,039 2,015 2,077 2,048 1,837 1,873 2,060 2,049 2,207
Total Noncurrent Assets
19,244 19,983 19,411 17,684 17,837 17,287 16,735 14,766 14,827 14,645 15,765
Goodwill
9,934 10,644 10,668 9,594 9,600 9,262 8,919 8,580 8,819 8,951 9,947
Intangible Assets
8,746 8,785 8,353 7,685 7,258 7,056 5,534 5,064 4,856 4,598 4,717
Other Noncurrent Operating Assets
564 554 389 405 980 969 1,005 1,122 1,152 1,096 1,100
Total Liabilities & Shareholders' Equity
27,161 26,684 26,014 24,127 24,639 24,418 23,456 21,066 21,497 21,365 23,092
Total Liabilities
17,271 17,015 14,279 12,851 12,246 12,218 10,790 9,039 9,009 8,889 10,386
Total Current Liabilities
1,618 2,382 3,070 2,421 3,442 2,557 3,468 2,358 2,857 2,451 2,584
Short-Term Debt
0.00 576 1,225 525 1,500 500 1,605 544 900 863 587
Accounts Payable
285 365 330 363 401 330 307 354 411 195 303
Current Deferred & Payable Income Tax Liabilities
147 184 165 142 127 60 62 39 - - 0.00
Current Employee Benefit Liabilities
- - - - - - - - - - 477
Other Current Liabilities
1,186 1,258 1,349 1,391 1,414 1,667 1,317 1,421 1,547 1,393 1,217
Total Noncurrent Liabilities
15,653 14,633 11,209 10,429 8,804 9,661 7,322 6,681 6,151 6,438 7,802
Long-Term Debt
11,497 10,666 8,918 8,414 6,721 7,627 5,464 5,152 4,868 5,342 6,932
Noncurrent Deferred Revenue
- 474 744 666 685 588 583 421 - - 0.00
Noncurrent Deferred & Payable Income Tax Liabilities
3,150 3,031 1,102 1,000 840 790 559 475 358 353 244
Other Noncurrent Operating Liabilities
1,006 463 446 350 558 656 549 633 926 744 626
Commitments & Contingencies
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests
9,889 9,670 11,736 11,276 12,393 12,199 12,666 12,027 12,488 12,476 12,706
Total Preferred & Common Equity
9,888 9,669 11,736 11,271 12,388 12,194 12,661 12,020 12,481 12,468 12,698
Total Common Equity
9,888 9,669 11,736 11,271 12,388 12,194 12,661 12,020 12,481 12,468 12,698
Common Stock
8,198 8,372 8,518 8,689 8,923 9,125 9,318 9,508 9,849 10,041 10,182
Retained Earnings
8,348 8,467 10,023 9,491 10,427 10,087 10,292 9,559 10,385 11,095 11,611
Treasury Stock
-6,329 -6,736 -6,722 -6,722 -6,721 -6,720 -6,718 -6,867 -7,562 -8,406 -8,889
Accumulated Other Comprehensive Income / (Loss)
-329 -434 -83 -187 -242 -298 -232 -179 -191 -263 -206
Noncontrolling Interest
1.50 1.00 -0.30 4.80 4.70 5.20 5.70 6.70 7.70 8.10 8.10

Quarterly Balance Sheets for Zimmer Biomet

This table presents Zimmer Biomet's assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q2 2023 Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q1 2026
Period end date 6/30/2023 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 3/31/2026
Total Assets
21,294 21,217 21,497 21,452 21,520 21,720 21,365 22,184 22,865 23,488 22,722
Total Current Assets
4,388 4,372 4,610 4,632 4,639 4,864 4,672 5,590 5,054 5,835 4,963
Cash & Equivalents
320 292 416 393 420 569 526 1,385 557 1,293 424
Accounts Receivable
1,367 1,341 1,442 1,446 1,418 1,482 1,481 1,533 1,611 1,598 1,729
Inventories, net
2,276 2,323 2,385 2,388 2,370 2,369 2,235 2,244 2,454 2,484 2,247
Prepaid Expenses
425 416 366 404 431 445 430 428 431 460 563
Current Deferred & Refundable Income Taxes
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Plant, Property, & Equipment, net
1,975 2,032 2,060 2,091 2,103 2,107 2,049 2,065 2,176 2,194 2,212
Total Noncurrent Assets
14,931 14,813 14,827 14,730 14,778 14,749 14,645 14,529 15,636 15,459 15,547
Goodwill
8,744 8,710 8,819 8,792 8,825 8,912 8,951 8,989 9,710 9,702 9,932
Intangible Assets
5,028 4,892 4,856 4,734 4,707 4,665 4,598 4,468 4,891 4,740 4,548
Other Noncurrent Operating Assets
1,160 1,211 1,152 1,204 1,246 1,172 1,096 1,072 1,035 1,017 1,068
Total Liabilities & Shareholders' Equity
21,294 21,217 21,497 21,452 21,520 21,720 21,365 22,184 22,865 23,488 22,722
Total Liabilities
8,916 8,699 9,009 8,846 8,771 9,337 8,889 9,780 10,331 10,722 10,040
Total Current Liabilities
2,234 2,072 2,857 2,797 3,608 3,571 2,451 2,295 2,700 2,403 2,864
Short-Term Debt
520 355 900 970 1,878 1,713 863 600 820 600 1,176
Accounts Payable
355 320 411 370 342 322 195 301 349 315 361
Current Deferred & Payable Income Tax Liabilities
82 97 - 70 0.00 0.00 - 0.00 0.00 0.00 0.00
Current Employee Benefit Liabilities
- - - - - - - - - - 294
Other Current Liabilities
1,278 1,300 1,547 1,386 1,389 1,536 1,393 1,394 1,531 1,488 1,033
Total Noncurrent Liabilities
6,682 6,628 6,151 6,049 5,162 5,766 6,438 7,485 7,631 8,319 7,176
Long-Term Debt
5,189 5,127 4,868 4,826 3,957 4,738 5,342 6,576 6,753 7,513 6,295
Noncurrent Deferred Revenue
376 403 - 276 0.00 0.00 - 0.00 0.00 0.00 0.00
Noncurrent Deferred & Payable Income Tax Liabilities
475 465 358 370 0.00 0.00 353 0.00 0.00 0.00 250
Other Noncurrent Operating Liabilities
642 632 926 577 1,205 1,028 744 909 879 806 631
Commitments & Contingencies
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests
12,379 12,518 12,488 12,606 12,749 12,383 12,476 12,404 12,534 12,766 12,682
Total Preferred & Common Equity
12,372 12,511 12,481 12,598 12,741 12,375 12,468 12,395 12,525 12,757 12,673
Total Common Equity
12,372 12,511 12,481 12,598 12,741 12,375 12,468 12,395 12,525 12,757 12,673
Common Stock
9,769 9,805 9,849 9,949 9,978 10,021 10,041 10,090 10,111 10,159 10,203
Retained Earnings
9,902 10,015 10,385 10,509 10,703 10,904 11,095 11,230 11,335 11,519 11,803
Treasury Stock
-7,122 -7,122 -7,562 -7,649 -7,744 -8,348 -8,406 -8,637 -8,637 -8,637 -9,141
Accumulated Other Comprehensive Income / (Loss)
-178 -187 -191 -211 -195 -202 -263 -287 -285 -284 -190
Noncontrolling Interest
7.10 7.20 7.70 8.10 8.40 8.50 8.10 8.70 9.30 9.50 8.20

Annual Metrics And Ratios for Zimmer Biomet

This table displays calculated financial ratios and metrics derived from Zimmer Biomet's official financial filings.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Growth Metrics
- - - - - - - - - - -
Revenue Growth
28.34% 26.96% 2.47% 1.66% 0.62% -23.24% 11.42% 1.65% 6.55% 3.85% 7.20%
EBITDA Growth
-16.36% 56.97% 3.27% -42.85% 102.02% -53.00% 80.07% -17.43% 48.53% 1.39% -1.49%
EBIT Growth
-56.55% 75.33% 4.68% -97.70% 6,123.63% -90.56% 716.18% -34.87% 123.19% -1.09% -10.44%
NOPAT Growth
-43.85% 40.35% 398.45% -99.24% 5,905.63% -95.91% 1,220.38% -34.57% 144.21% -8.51% -16.99%
Net Income Growth
-79.67% 108.34% 495.34% -120.92% 398.31% -112.14% 392.29% -42.38% 342.52% -11.74% -21.99%
EPS Growth
-81.67% 96.10% 489.40% -120.90% 394.09% -112.25% 385.07% -42.41% 343.64% -9.22% -19.86%
Operating Cash Flow Growth
-19.87% 92.07% -3.06% 10.43% -9.25% -32.17% 30.56% -3.43% 16.62% -5.20% 13.19%
Free Cash Flow Firm Growth
-2,023.92% 100.86% 1,731.09% -16.55% -35.69% -51.61% 346.15% -54.43% -31.90% 9.90% -167.58%
Invested Capital Growth
214.63% 2.60% 5.31% -7.88% 1.65% -2.36% -8.19% -3.22% 2.84% 1.77% 8.14%
Revenue Q/Q Growth
13.44% 0.14% 3.79% -1.96% 0.69% -13.27% 9.44% 0.70% 1.58% 1.10% 2.75%
EBITDA Q/Q Growth
22.92% -6.89% -7.64% -41.86% 113.73% -4.41% -9.31% -10.04% 20.62% 1.75% -6.75%
EBIT Q/Q Growth
5.23% -11.75% -17.34% -97.64% 18,079.37% 250.49% -24.82% -22.20% 40.68% 1.32% -13.87%
NOPAT Q/Q Growth
15.46% 1.50% 191.31% -99.19% 19,801.02% 901.20% -33.53% -37.04% 104.24% -14.61% -11.47%
Net Income Q/Q Growth
-13.29% -15.76% 178.17% -121.62% 1,324.57% 8.28% -50.99% -16.79% 115.85% -16.59% -12.43%
EPS Q/Q Growth
-20.62% -17.49% 178.13% -121.65% 1,263.83% 0.00% 0.00% -17.29% 115.93% -15.62% -11.69%
Operating Cash Flow Q/Q Growth
7.99% 11.22% -12.42% -1.32% 2.84% -10.57% 3.04% -6.44% 27.82% -5.19% 0.66%
Free Cash Flow Firm Q/Q Growth
1.55% 189.18% 34.76% -29.59% 11.44% -26.66% 123.73% -59.69% 134.94% 6.54% -103.20%
Invested Capital Q/Q Growth
-1.67% -2.70% 4.70% -5.86% 0.39% 1.68% -7.12% -0.41% 0.75% -0.60% 0.24%
Profitability Metrics
- - - - - - - - - - -
Gross Margin
69.98% 68.72% 72.67% 71.36% 71.78% 70.23% 71.29% 70.90% 71.82% 71.46% 69.71%
EBITDA Margin
19.05% 23.56% 23.74% 13.35% 26.79% 16.41% 26.51% 21.54% 30.02% 29.31% 26.94%
Operating Margin
7.79% 10.78% 10.24% 0.43% 14.25% 1.36% 12.60% 10.03% 17.28% 16.74% 13.34%
EBIT Margin
7.18% 9.91% 10.12% 0.23% 14.19% 1.74% 12.78% 8.19% 17.15% 16.34% 13.65%
Profit (Net Income) Margin
2.44% 4.00% 23.24% -4.78% 14.18% -2.24% 5.88% 3.33% 13.85% 11.77% 8.57%
Tax Burden Percent
95.43% 76.23% 390.31% 139.91% 124.92% 130.61% 80.48% 57.35% 95.94% 87.19% 84.87%
Interest Burden Percent
35.59% 52.96% 58.82% -1,489.56% 79.97% -98.41% 57.19% 71.00% 84.15% 82.62% 73.94%
Effective Tax Rate
4.57% 23.77% -290.31% 0.00% -24.92% 0.00% 10.72% 27.83% 3.95% 12.68% 15.13%
Return on Invested Capital (ROIC)
3.42% 3.13% 14.99% 0.12% 7.16% 0.29% 4.10% 2.85% 6.98% 6.24% 4.93%
ROIC Less NNEP Spread (ROIC-NNEP)
-2.82% -0.01% 2.07% -4.36% 3.55% -2.33% -1.72% -2.28% 3.17% 2.27% 1.33%
Return on Net Nonoperating Assets (RNNOA)
-1.65% -0.01% 1.96% -3.41% 2.40% -1.41% -0.87% -0.98% 1.38% 1.00% 0.67%
Return on Equity (ROE)
1.78% 3.11% 16.94% -3.30% 9.56% -1.12% 3.23% 1.87% 8.35% 7.24% 5.60%
Cash Return on Invested Capital (CROIC)
-100.10% 0.56% 9.82% 8.31% 5.53% 2.69% 12.64% 6.12% 4.18% 4.49% -2.89%
Operating Return on Assets (OROA)
2.34% 2.80% 3.00% 0.07% 4.65% 0.44% 3.65% 2.55% 5.96% 5.85% 5.05%
Return on Assets (ROA)
0.79% 1.13% 6.88% -1.51% 4.64% -0.56% 1.68% 1.04% 4.81% 4.22% 3.17%
Return on Common Equity (ROCE)
1.78% 3.11% 16.94% -3.30% 9.56% -1.12% 3.23% 1.87% 8.35% 7.24% 5.60%
Return on Equity Simple (ROE_SIMPLE)
1.48% 3.15% 15.45% -3.37% 9.13% -1.13% 3.17% 1.93% 8.20% 7.25% 0.00%
Net Operating Profit after Tax (NOPAT)
446 626 3,120 24 1,421 58 768 503 1,227 1,123 932
NOPAT Margin
7.44% 8.22% 39.98% 0.30% 17.80% 0.95% 11.25% 7.24% 16.60% 14.62% 11.32%
Net Nonoperating Expense Percent (NNEP)
6.24% 3.14% 12.92% 4.47% 3.62% 2.62% 5.83% 5.13% 3.81% 3.97% 3.60%
Return On Investment Capital (ROIC_SIMPLE)
2.09% 2.99% 14.26% 0.12% 6.89% 0.29% 3.89% 2.84% 6.72% 6.01% 4.61%
Cost of Revenue to Revenue
30.02% 31.28% 27.33% 28.64% 28.22% 29.77% 28.71% 29.10% 28.18% 28.54% 30.29%
SG&A Expenses to Revenue
38.08% 38.67% 39.79% 42.60% 41.89% 44.27% 41.65% 39.79% 38.39% 38.16% 39.57%
R&D to Revenue
4.48% 4.80% 4.74% 4.94% 5.63% 5.27% 6.38% 5.85% 6.20% 5.70% 5.57%
Operating Expenses to Revenue
62.19% 57.94% 62.42% 70.94% 57.53% 68.87% 58.69% 60.87% 54.54% 54.72% 56.37%
Earnings before Interest and Taxes (EBIT)
430 755 790 18 1,133 107 873 568 1,268 1,255 1,124
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)
1,143 1,794 1,853 1,059 2,139 1,005 1,810 1,495 2,220 2,251 2,217
Valuation Ratios
- - - - - - - - - - -
Price to Book Value (P/BV)
1.92 1.96 1.92 1.75 2.33 2.48 1.99 2.19 2.02 1.69 1.40
Price to Tangible Book Value (P/TBV)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Price to Revenue (P/Rev)
3.16 2.49 2.89 2.48 3.62 4.93 3.70 3.79 3.41 2.74 2.16
Price to Earnings (P/E)
129.12 61.88 12.43 0.00 25.52 0.00 62.96 114.25 24.65 23.31 25.27
Dividend Yield
0.94% 1.02% 0.86% 0.99% 0.68% 0.66% 0.79% 0.77% 0.80% 0.91% 1.07%
Earnings Yield
0.77% 1.62% 8.04% 0.00% 3.92% 0.00% 1.59% 0.88% 4.06% 4.29% 3.96%
Enterprise Value to Invested Capital (EV/IC)
1.46 1.46 1.51 1.43 1.82 1.92 1.78 1.82 1.71 1.47 1.26
Enterprise Value to Revenue (EV/Rev)
4.81 3.88 4.12 3.54 4.57 6.12 4.68 4.56 4.14 3.48 3.01
Enterprise Value to EBITDA (EV/EBITDA)
25.25 16.47 17.37 26.54 17.06 37.33 17.65 21.18 13.77 11.87 11.16
Enterprise Value to EBIT (EV/EBIT)
67.04 39.14 40.73 1,543.84 32.21 351.02 36.62 55.69 24.11 21.29 22.03
Enterprise Value to NOPAT (EV/NOPAT)
64.71 47.19 10.31 1,187.57 25.68 645.08 41.60 62.99 24.92 23.80 26.56
Enterprise Value to Operating Cash Flow (EV/OCF)
33.96 18.10 20.33 16.08 23.01 34.89 22.75 23.34 19.33 17.82 14.59
Enterprise Value to Free Cash Flow (EV/FCFF)
0.00 264.69 15.74 16.48 33.27 70.71 13.49 29.33 41.61 33.08 0.00
Leverage & Solvency
- - - - - - - - - - -
Debt to Equity
1.16 1.16 0.86 0.79 0.66 0.67 0.56 0.47 0.46 0.50 0.59
Long-Term Debt to Equity
1.16 1.10 0.76 0.75 0.54 0.63 0.43 0.43 0.39 0.43 0.55
Financial Leverage
0.58 1.05 0.94 0.78 0.68 0.61 0.51 0.43 0.44 0.44 0.50
Leverage Ratio
2.24 2.75 2.46 2.18 2.06 1.99 1.93 1.80 1.74 1.72 1.77
Compound Leverage Factor
0.80 1.46 1.45 -32.46 1.65 -1.96 1.10 1.28 1.46 1.42 1.31
Debt to Total Capital
53.76% 53.76% 46.36% 44.22% 39.88% 39.98% 35.82% 32.14% 31.59% 33.21% 37.18%
Short-Term Debt to Total Capital
0.00% 2.75% 5.60% 2.60% 7.28% 2.46% 8.13% 3.07% 4.93% 4.62% 2.90%
Long-Term Debt to Total Capital
53.76% 51.01% 40.76% 41.62% 32.61% 37.52% 27.69% 29.07% 26.66% 28.59% 34.27%
Preferred Equity to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital
0.01% 0.00% 0.00% 0.02% 0.02% 0.03% 0.03% 0.04% 0.04% 0.04% 0.04%
Common Equity to Total Capital
46.23% 46.24% 53.64% 55.76% 60.10% 59.99% 64.15% 67.82% 68.36% 66.74% 62.78%
Debt to EBITDA
10.06 6.27 5.47 8.44 3.84 8.08 3.91 3.81 2.60 2.76 3.39
Net Debt to EBITDA
8.64 5.91 5.19 7.93 3.56 7.29 3.70 3.56 2.41 2.52 3.12
Long-Term Debt to EBITDA
10.06 5.95 4.81 7.95 3.14 7.59 3.02 3.45 2.19 2.37 3.13
Debt to NOPAT
25.78 17.96 3.25 377.80 5.79 139.70 9.20 11.34 4.70 5.53 8.07
Net Debt to NOPAT
22.14 16.95 3.08 354.86 5.35 125.91 8.71 10.59 4.36 5.06 7.43
Long-Term Debt to NOPAT
25.78 17.04 2.86 355.61 4.73 131.11 7.11 10.25 3.97 4.76 7.44
Altman Z-Score
1.55 1.59 1.96 1.90 2.55 2.45 2.50 2.92 2.99 2.82 2.38
Noncontrolling Interest Sharing Ratio
0.02% 0.01% 0.00% 0.02% 0.04% 0.04% 0.04% 0.05% 0.06% 0.06% 0.06%
Liquidity Ratios
- - - - - - - - - - -
Current Ratio
3.62 1.96 1.49 1.83 1.37 1.99 1.41 1.88 1.61 1.91 1.98
Quick Ratio
1.90 0.94 0.67 0.75 0.58 0.88 0.47 0.75 0.65 0.82 0.89
Cash Flow Metrics
- - - - - - - - - - -
Free Cash Flow to Firm (FCFF)
-13,036 112 2,043 1,705 1,097 531 2,368 1,079 735 808 -546
Operating Cash Flow to CapEx
868.92% 883.70% 1,014.29% 1,074.00% 765.72% 961.22% 977.92% 721.77% 543.32% 735.72% 755.95%
Free Cash Flow to Firm to Interest Expense
-45.48 0.31 6.28 5.89 4.83 2.50 6.34 6.55 3.65 3.70 -1.86
Operating Cash Flow to Interest Expense
2.97 4.60 4.86 6.04 6.99 5.07 3.76 8.23 7.86 6.88 5.80
Operating Cash Flow Less CapEx to Interest Expense
2.62 4.08 4.38 5.48 6.08 4.54 3.38 7.09 6.41 5.94 5.03
Efficiency Ratios
- - - - - - - - - - -
Asset Turnover
0.33 0.28 0.30 0.32 0.33 0.25 0.29 0.31 0.35 0.36 0.37
Accounts Receivable Turnover
5.09 4.99 4.96 5.63 6.05 4.35 5.03 5.26 5.24 5.25 5.17
Inventory Turnover
1.04 1.13 1.06 1.05 0.97 0.75 0.85 0.94 0.92 0.95 1.10
Fixed Asset Turnover
3.58 3.71 3.83 3.91 3.90 2.97 3.52 3.74 3.76 3.74 3.87
Accounts Payable Turnover
8.37 7.34 6.14 6.56 5.90 4.99 6.16 6.11 5.45 7.24 10.02
Days Sales Outstanding (DSO)
71.77 73.12 73.64 64.87 60.35 83.89 72.50 69.45 69.70 69.47 70.62
Days Inventory Outstanding (DIO)
349.41 322.85 344.63 347.41 376.04 483.76 428.11 388.15 396.95 384.83 330.92
Days Payable Outstanding (DPO)
43.58 49.75 59.44 55.65 61.86 73.12 59.25 59.70 66.97 50.41 36.42
Cash Conversion Cycle (CCC)
377.60 346.22 358.82 356.63 374.54 494.53 441.36 397.91 399.67 403.90 365.12
Capital & Investment Metrics
- - - - - - - - - - -
Invested Capital
19,763 20,277 21,354 19,672 19,996 19,524 17,924 17,348 17,840 18,155 19,633
Invested Capital Turnover
0.46 0.38 0.37 0.39 0.40 0.31 0.36 0.39 0.42 0.43 0.44
Increase / (Decrease) in Invested Capital
13,482 514 1,076 -1,682 324 -473 -1,600 -577 492 315 1,478
Enterprise Value (EV)
28,856 29,538 32,170 28,098 36,483 37,524 31,949 31,651 30,576 26,715 24,756
Market Capitalization
18,981 18,930 22,553 19,697 28,875 30,194 25,252 26,324 25,216 21,028 17,820
Book Value per Share
$48.52 $48.27 $57.96 $55.26 $60.23 $58.83 $60.60 $57.28 $59.72 $62.63 $64.07
Tangible Book Value per Share
($43.15) ($48.73) ($35.99) ($29.45) ($21.73) ($19.89) ($8.58) ($7.74) ($5.72) ($5.43) ($9.92)
Total Capital
21,387 20,911 21,878 20,215 20,614 20,326 19,735 17,724 18,256 18,681 20,225
Total Debt
11,497 11,241 10,143 8,939 8,221 8,127 7,069 5,697 5,768 6,205 7,519
Total Long-Term Debt
11,497 10,666 8,918 8,414 6,721 7,627 5,464 5,152 4,868 5,342 6,932
Net Debt
9,874 10,607 9,618 8,396 7,604 7,324 6,691 5,321 5,352 5,679 6,927
Capital Expenditures (CapEx)
98 185 156 163 207 112 144 188 291 204 225
Debt-free, Cash-free Net Working Capital (DFCFNWC)
2,612 2,224 2,196 1,988 2,165 2,224 2,644 2,238 2,236 2,558 2,531
Debt-free Net Working Capital (DFNWC)
4,236 2,858 2,720 2,531 2,782 3,026 3,022 2,613 2,652 3,084 3,123
Net Working Capital (NWC)
4,236 2,282 1,495 2,006 1,282 2,526 1,417 2,069 1,752 2,221 2,536
Net Nonoperating Expense (NNE)
300 321 1,306 403 289 196 366 271 203 219 227
Net Nonoperating Obligations (NNO)
9,874 10,607 9,618 8,396 7,604 7,324 5,258 5,321 5,352 5,679 6,927
Total Depreciation and Amortization (D&A)
712 1,039 1,063 1,041 1,006 898 938 926 952 996 1,094
Debt-free, Cash-free Net Working Capital to Revenue
43.55% 29.20% 28.14% 25.06% 27.12% 36.30% 38.73% 32.24% 30.24% 33.31% 30.75%
Debt-free Net Working Capital to Revenue
70.62% 37.53% 34.86% 31.91% 34.86% 49.39% 44.27% 37.66% 35.87% 40.16% 37.94%
Net Working Capital to Revenue
70.62% 29.97% 19.16% 25.29% 16.07% 41.23% 20.76% 29.81% 23.70% 28.92% 30.81%
Earnings Adjustments
- - - - - - - - - - -
Adjusted Basic Earnings per Share
$0.78 $1.53 $8.98 ($1.86) $5.52 ($0.67) $1.93 $1.10 $4.91 $4.45 $3.56
Adjusted Weighted Average Basic Shares Outstanding
187.40M 200M 201.90M 203.50M 205.10M 207M 208.60M 209.60M 208.70M 203.10M 198M
Adjusted Diluted Earnings per Share
$0.77 $1.51 $8.90 ($1.86) $5.47 ($0.67) $1.91 $1.10 $4.88 $4.43 $3.55
Adjusted Weighted Average Diluted Shares Outstanding
189.80M 202.40M 203.70M 203.50M 206.70M 207M 210.40M 210.30M 209.70M 203.90M 198.70M
Adjusted Basic & Diluted Earnings per Share
$0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding
198.83M 201.10M 203.15M 204.43M 206.40M 207.86M 209.18M 208.98M 205.08M 199.06M 195.65M
Normalized Net Operating Profit after Tax (NOPAT)
1,247 1,034 804 733 880 493 895 860 1,373 1,314 1,086
Normalized NOPAT Margin
20.79% 13.58% 10.30% 9.24% 11.03% 8.05% 13.11% 12.40% 18.57% 17.11% 13.19%
Pre Tax Income Margin
2.55% 5.25% 5.95% -3.42% 11.35% -1.72% 7.31% 5.81% 14.43% 13.50% 10.09%
Debt Service Ratios
- - - - - - - - - - -
EBIT to Interest Expense
1.50 2.13 2.43 0.06 4.99 0.50 2.34 3.45 6.30 5.76 3.84
NOPAT to Interest Expense
1.56 1.76 9.59 0.08 6.26 0.27 2.06 3.05 6.10 5.15 3.18
EBIT Less CapEx to Interest Expense
1.16 1.61 1.95 -0.50 4.08 -0.02 1.95 2.31 4.86 4.82 3.07
NOPAT Less CapEx to Interest Expense
1.21 1.24 9.11 -0.48 5.35 -0.25 1.67 1.91 4.65 4.22 2.42
Payout Ratios
- - - - - - - - - - -
Dividend Payout Ratio
107.46% 61.85% 10.68% -51.46% 17.38% -144.47% 85.93% 86.95% 19.62% 21.69% 26.99%
Augmented Payout Ratio
210.05% 198.26% 10.68% -51.46% 17.38% -144.47% 85.93% 141.57% 87.22% 117.73% 96.06%

Quarterly Metrics And Ratios for Zimmer Biomet

This table displays calculated financial ratios and metrics derived from Zimmer Biomet's official financial filings.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
DEI Shares Outstanding
- - - - - - - - - - 195,652,004.00
DEI Adjusted Shares Outstanding
- - - - - - - - - - 195,652,004.00
DEI Earnings Per Adjusted Shares Outstanding
- - - - - - - - - - 1.22
Growth Metrics
- - - - - - - - - - -
Revenue Growth
5.02% 6.30% 3.18% 3.87% 4.03% 4.29% 1.05% 6.97% 9.71% 10.90% 9.30%
EBITDA Growth
13.36% 193.33% -11.01% 5.41% 4.67% 6.72% 8.96% -3.49% 19.18% -26.14% 16.48%
EBIT Growth
22.97% 1,139.13% -20.66% 7.58% 5.25% 4.87% 11.06% -13.98% 24.60% -51.58% 25.41%
NOPAT Growth
-26.18% 2,737.67% -19.56% 13.07% 52.74% -38.15% 9.05% -27.50% -3.81% -32.68% 26.71%
Net Income Growth
-16.13% 420.51% -25.77% 15.84% 53.10% -42.92% 5.57% -37.07% -7.31% -41.80% 30.82%
EPS Growth
-16.30% 422.58% -24.32% 18.00% 59.74% -41.00% 8.33% -34.75% -5.69% -39.83% 34.07%
Operating Cash Flow Growth
-25.11% 140.95% -25.90% 6.18% 17.21% -13.95% 67.89% 2.38% 5.81% 2.19% -6.11%
Free Cash Flow Firm Growth
-104.20% -94.59% -133.36% -146.47% -182.32% -73.51% 126.15% -942.17% -305.09% -15,892.03% -2,753.22%
Invested Capital Growth
1.65% 2.84% 2.23% 2.23% 3.14% 1.77% 1.03% 7.63% 7.23% 8.14% 8.42%
Revenue Q/Q Growth
-6.20% 10.63% -2.62% 2.79% -6.07% 10.91% -5.64% 8.81% -3.65% 12.11% -7.00%
EBITDA Q/Q Growth
-9.60% 12.55% -12.40% 18.26% -10.23% 14.75% -10.56% 4.75% 10.86% -28.88% 41.04%
EBIT Q/Q Growth
-17.66% 23.74% -20.56% 32.92% -19.45% 23.30% -15.87% 2.95% 16.68% -52.09% 117.89%
NOPAT Q/Q Growth
-20.78% 163.90% -59.12% 32.30% 7.02% 6.86% -27.92% -12.04% 41.98% -25.21% 35.67%
Net Income Q/Q Growth
-22.38% 157.47% -58.75% 40.51% 2.59% -4.01% -23.88% -16.04% 51.11% -39.63% 70.80%
EPS Q/Q Growth
-23.00% 159.74% -58.00% 40.48% 4.24% -4.07% -22.88% -15.38% 50.65% -38.79% 71.83%
Operating Cash Flow Q/Q Growth
-2.96% 74.29% -61.25% 62.02% 7.12% 27.95% -24.39% -1.20% 10.71% 23.57% -30.54%
Free Cash Flow Firm Q/Q Growth
-136.95% 133.43% -692.21% 36.49% -124.50% 103.14% 484.57% -2,631.38% 12.74% -22.30% 1.79%
Invested Capital Q/Q Growth
-0.34% 0.75% 0.95% 0.86% 0.55% -0.60% 0.22% 7.44% 0.19% 0.24% 0.48%
Profitability Metrics
- - - - - - - - - - -
Gross Margin
70.43% 72.22% 72.88% 71.49% 70.47% 71.00% 71.20% 71.49% 72.05% 64.68% 72.39%
EBITDA Margin
29.17% 29.68% 26.70% 30.72% 29.36% 30.37% 28.79% 27.71% 31.89% 20.23% 30.68%
Operating Margin
15.20% 18.26% 14.07% 18.09% 15.32% 19.23% 15.31% 14.44% 17.55% 6.89% 17.88%
EBIT Margin
15.42% 17.25% 14.07% 18.19% 15.60% 17.34% 15.46% 14.63% 17.72% 7.57% 17.74%
Profit (Net Income) Margin
9.28% 21.59% 9.15% 12.50% 13.66% 11.82% 9.53% 7.36% 11.54% 6.21% 11.41%
Tax Burden Percent
74.22% 147.24% 80.33% 80.34% 108.16% 82.73% 79.48% 68.03% 82.70% 142.24% 79.02%
Interest Burden Percent
81.07% 85.03% 80.93% 85.54% 80.92% 82.36% 77.57% 73.91% 78.74% 57.68% 81.39%
Effective Tax Rate
25.73% -47.52% 19.67% 19.56% -8.21% 16.92% 20.31% 31.70% 17.19% -40.82% 20.91%
Return on Invested Capital (ROIC)
4.68% 11.32% 4.73% 6.09% 7.00% 6.82% 5.19% 4.10% 6.15% 4.22% 6.27%
ROIC Less NNEP Spread (ROIC-NNEP)
4.00% 9.38% 3.98% 5.36% 6.04% 5.29% 4.28% 3.26% 5.21% 2.98% 5.38%
Return on Net Nonoperating Assets (RNNOA)
1.67% 4.08% 1.75% 2.30% 2.68% 2.34% 1.92% 1.60% 2.63% 1.49% 2.76%
Return on Equity (ROE)
6.35% 15.40% 6.48% 8.40% 9.69% 9.15% 7.10% 5.70% 8.78% 5.72% 9.03%
Cash Return on Invested Capital (CROIC)
1.78% 4.18% 4.42% 4.53% 4.21% 4.49% 5.28% -1.68% -1.42% -2.89% -2.84%
Operating Return on Assets (OROA)
5.28% 5.99% 4.91% 6.39% 5.52% 6.21% 5.46% 5.16% 6.28% 2.80% 6.64%
Return on Assets (ROA)
3.17% 7.50% 3.19% 4.39% 4.83% 4.23% 3.36% 2.60% 4.09% 2.30% 4.27%
Return on Common Equity (ROCE)
6.35% 15.39% 6.47% 8.39% 9.68% 9.15% 7.10% 5.70% 8.78% 5.71% 9.02%
Return on Equity Simple (ROE_SIMPLE)
3.79% 0.00% 7.65% 7.83% 8.76% 0.00% 7.37% 0.00% 0.00% 0.00% 0.00%
Net Operating Profit after Tax (NOPAT)
198 523 214 283 302 323 233 205 291 218 295
NOPAT Margin
11.29% 26.93% 11.31% 14.55% 16.58% 15.97% 12.20% 9.86% 14.54% 9.70% 14.15%
Net Nonoperating Expense Percent (NNEP)
0.68% 1.94% 0.75% 0.74% 0.96% 1.52% 0.91% 0.84% 0.94% 1.24% 0.89%
Return On Investment Capital (ROIC_SIMPLE)
1.10% 2.86% 1.16% 1.52% 1.61% 1.73% 1.19% 1.02% 1.39% 1.08% 1.46%
Cost of Revenue to Revenue
29.57% 27.78% 27.12% 28.51% 29.53% 29.00% 28.80% 28.51% 27.95% 35.32% 27.61%
SG&A Expenses to Revenue
38.49% 37.23% 38.97% 37.96% 38.90% 36.91% 39.75% 39.22% 40.54% 38.87% 40.73%
R&D to Revenue
6.67% 5.84% 5.71% 5.63% 6.12% 5.36% 5.79% 5.45% 5.79% 5.29% 4.96%
Operating Expenses to Revenue
55.22% 53.97% 58.81% 53.41% 55.15% 51.77% 55.89% 57.05% 54.50% 57.80% 54.50%
Earnings before Interest and Taxes (EBIT)
270 335 266 353 285 351 295 304 355 170 370
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)
512 576 504 597 536 615 550 576 638 454 640
Valuation Ratios
- - - - - - - - - - -
Price to Book Value (P/BV)
1.85 2.02 2.17 1.74 1.77 1.69 1.82 1.44 1.53 1.40 1.40
Price to Tangible Book Value (P/TBV)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Price to Revenue (P/Rev)
3.19 3.41 3.68 2.95 2.89 2.74 2.93 2.30 2.44 2.16 2.10
Price to Earnings (P/E)
49.01 24.65 28.46 22.32 20.27 23.31 24.71 21.92 24.30 25.27 23.23
Dividend Yield
0.86% 0.80% 0.73% 0.89% 0.89% 0.91% 0.85% 1.06% 0.97% 1.07% 1.06%
Earnings Yield
2.04% 4.06% 3.51% 4.48% 4.93% 4.29% 4.05% 4.56% 4.12% 3.96% 4.31%
Enterprise Value to Invested Capital (EV/IC)
1.60 1.71 1.82 1.52 1.52 1.47 1.56 1.28 1.34 1.26 1.25
Enterprise Value to Revenue (EV/Rev)
3.90 4.14 4.40 3.67 3.66 3.48 3.68 3.19 3.29 3.01 2.94
Enterprise Value to EBITDA (EV/EBITDA)
15.43 13.77 15.21 12.64 12.58 11.87 12.34 11.00 11.08 11.16 10.72
Enterprise Value to EBIT (EV/EBIT)
31.50 24.11 27.36 22.59 22.47 21.29 22.06 20.27 20.19 22.03 20.65
Enterprise Value to NOPAT (EV/NOPAT)
47.27 24.92 27.82 22.84 21.16 23.80 24.79 23.40 25.02 26.56 24.91
Enterprise Value to Operating Cash Flow (EV/OCF)
22.95 19.33 21.84 18.15 17.59 17.82 17.13 15.05 15.62 14.59 14.79
Enterprise Value to Free Cash Flow (EV/FCFF)
90.81 41.61 41.68 33.94 36.71 33.08 29.62 0.00 0.00 0.00 0.00
Leverage & Solvency
- - - - - - - - - - -
Debt to Equity
0.44 0.46 0.46 0.46 0.52 0.50 0.58 0.60 0.64 0.59 0.59
Long-Term Debt to Equity
0.41 0.39 0.38 0.31 0.38 0.43 0.53 0.54 0.59 0.55 0.50
Financial Leverage
0.42 0.44 0.44 0.43 0.44 0.44 0.45 0.49 0.51 0.50 0.51
Leverage Ratio
1.72 1.74 1.72 1.70 1.72 1.72 1.74 1.76 1.80 1.77 1.79
Compound Leverage Factor
1.39 1.48 1.40 1.46 1.40 1.41 1.35 1.30 1.42 1.02 1.46
Debt to Total Capital
30.46% 31.59% 31.50% 31.40% 34.25% 33.21% 36.65% 37.66% 38.86% 37.18% 37.07%
Short-Term Debt to Total Capital
1.97% 4.93% 5.27% 10.11% 9.10% 4.62% 3.06% 4.08% 2.87% 2.90% 5.84%
Long-Term Debt to Total Capital
28.48% 26.66% 26.23% 21.29% 25.16% 28.59% 33.59% 33.58% 35.98% 34.27% 31.24%
Preferred Equity to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital
0.04% 0.04% 0.04% 0.05% 0.05% 0.04% 0.04% 0.05% 0.05% 0.04% 0.04%
Common Equity to Total Capital
69.50% 68.36% 68.46% 68.56% 65.70% 66.74% 63.30% 62.29% 61.10% 62.78% 62.89%
Debt to EBITDA
2.98 2.60 2.69 2.67 2.92 2.76 3.13 3.33 3.41 3.39 3.24
Net Debt to EBITDA
2.82 2.41 2.50 2.47 2.66 2.52 2.52 3.08 2.87 3.12 3.05
Long-Term Debt to EBITDA
2.79 2.19 2.24 1.81 2.14 2.37 2.86 2.97 3.16 3.13 2.73
Debt to NOPAT
9.12 4.70 4.92 4.82 4.91 5.53 6.28 7.08 7.71 8.07 7.52
Net Debt to NOPAT
8.64 4.36 4.58 4.47 4.47 5.06 5.07 6.56 6.48 7.43 7.09
Long-Term Debt to NOPAT
8.53 3.97 4.09 3.27 3.60 4.76 5.75 6.31 7.14 7.44 6.34
Altman Z-Score
2.78 2.85 3.03 2.68 2.58 2.68 2.66 2.25 2.34 2.25 2.32
Noncontrolling Interest Sharing Ratio
0.05% 0.06% 0.06% 0.06% 0.06% 0.06% 0.07% 0.07% 0.07% 0.06% 0.07%
Liquidity Ratios
- - - - - - - - - - -
Current Ratio
2.11 1.61 1.66 1.29 1.36 1.91 2.44 1.87 2.43 1.98 1.73
Quick Ratio
0.79 0.65 0.66 0.51 0.57 0.82 1.27 0.80 1.20 0.89 0.75
Cash Flow Metrics
- - - - - - - - - - -
Free Cash Flow to Firm (FCFF)
-90 30 -178 -113 -254 7.98 47 -1,181 -1,030 -1,260 -1,238
Operating Cash Flow to CapEx
400.47% 936.94% 413.79% 700.95% 889.21% 983.11% 858.30% 754.89% 761.27% 691.71% 990.08%
Free Cash Flow to Firm to Interest Expense
-1.76 0.60 -3.52 -2.22 -4.68 0.13 0.70 -14.89 -13.67 -17.53 -17.99
Operating Cash Flow to Interest Expense
6.61 11.70 4.50 7.23 7.29 8.18 5.78 4.77 5.55 7.20 5.22
Operating Cash Flow Less CapEx to Interest Expense
4.96 10.45 3.41 6.20 6.47 7.35 5.11 4.14 4.82 6.16 4.70
Efficiency Ratios
- - - - - - - - - - -
Asset Turnover
0.34 0.35 0.35 0.35 0.35 0.36 0.35 0.35 0.35 0.37 0.37
Accounts Receivable Turnover
5.56 5.24 5.27 5.40 5.38 5.25 5.17 5.17 5.20 5.17 5.16
Inventory Turnover
0.93 0.92 0.91 0.91 0.91 0.95 0.96 0.94 0.94 1.10 1.12
Fixed Asset Turnover
3.80 3.76 3.73 3.69 3.67 3.74 3.70 3.66 3.72 3.87 3.93
Accounts Payable Turnover
6.32 5.45 5.46 6.10 6.68 7.24 6.64 6.57 7.18 10.02 7.61
Days Sales Outstanding (DSO)
65.67 69.70 69.24 67.55 67.81 69.47 70.64 70.57 70.16 70.62 70.79
Days Inventory Outstanding (DIO)
393.41 396.95 403.23 399.28 399.50 384.83 379.33 388.30 387.05 330.92 325.23
Days Payable Outstanding (DPO)
57.76 66.97 66.84 59.85 54.67 50.41 54.99 55.58 50.87 36.42 47.98
Cash Conversion Cycle (CCC)
401.32 399.67 405.62 406.98 412.64 403.90 394.97 403.29 406.34 365.12 348.05
Capital & Investment Metrics
- - - - - - - - - - -
Invested Capital
17,708 17,840 18,009 18,164 18,265 18,155 18,196 19,550 19,586 19,633 19,728
Invested Capital Turnover
0.41 0.42 0.42 0.42 0.42 0.43 0.43 0.42 0.42 0.44 0.44
Increase / (Decrease) in Invested Capital
288 492 392 396 557 315 186 1,386 1,321 1,478 1,533
Enterprise Value (EV)
28,401 30,576 32,809 27,651 27,825 26,715 28,330 25,027 26,342 24,756 24,746
Market Capitalization
23,204 25,216 27,397 22,228 21,935 21,028 22,530 18,002 19,512 17,820 17,691
Book Value per Share
$59.87 $59.72 $61.39 $61.93 $60.76 $62.63 $62.27 $63.31 $64.40 $64.07 $64.77
Tangible Book Value per Share
($5.22) ($5.72) ($4.52) ($3.84) ($5.91) ($5.43) ($5.33) ($10.49) ($8.51) ($9.92) ($9.23)
Total Capital
18,000 18,256 18,402 18,584 18,834 18,681 19,580 20,107 20,879 20,225 20,153
Total Debt
5,482 5,768 5,796 5,835 6,451 6,205 7,176 7,573 8,113 7,519 7,471
Total Long-Term Debt
5,127 4,868 4,826 3,957 4,738 5,342 6,576 6,753 7,513 6,932 6,295
Net Debt
5,190 5,352 5,403 5,415 5,882 5,679 5,792 7,016 6,820 6,927 7,047
Capital Expenditures (CapEx)
84 63 55 53 45 52 45 50 55 75 36
Debt-free, Cash-free Net Working Capital (DFCFNWC)
2,363 2,236 2,412 2,489 2,437 2,558 2,511 2,618 2,739 2,531 2,850
Debt-free Net Working Capital (DFNWC)
2,656 2,652 2,805 2,909 3,006 3,084 3,895 3,174 4,032 3,123 3,274
Net Working Capital (NWC)
2,301 1,752 1,835 1,031 1,293 2,221 3,295 2,354 3,432 2,536 2,098
Net Nonoperating Expense (NNE)
35 104 41 40 53 84 51 52 60 78 57
Net Nonoperating Obligations (NNO)
5,190 5,352 5,403 5,415 5,882 5,679 5,792 7,016 6,820 6,927 7,047
Total Depreciation and Amortization (D&A)
241 241 239 243 251 264 254 272 284 284 270
Debt-free, Cash-free Net Working Capital to Revenue
32.47% 30.24% 32.36% 33.08% 32.08% 33.31% 32.61% 33.41% 34.19% 30.75% 33.89%
Debt-free Net Working Capital to Revenue
36.48% 35.87% 37.63% 38.66% 39.57% 40.16% 50.60% 40.52% 50.33% 37.94% 38.94%
Net Working Capital to Revenue
31.60% 23.70% 24.62% 13.70% 17.02% 28.92% 42.80% 30.05% 42.84% 30.81% 24.95%
Earnings Adjustments
- - - - - - - - - - -
Adjusted Basic Earnings per Share
$0.78 $2.02 $0.84 $1.18 $1.23 $1.20 $0.92 $0.77 $1.17 $0.70 $1.22
Adjusted Weighted Average Basic Shares Outstanding
208.90M 208.70M 205.20M 205.70M 202.30M 203.10M 198.90M 197.90M 198.10M 198M 195M
Adjusted Diluted Earnings per Share
$0.77 $2.00 $0.84 $1.18 $1.23 $1.18 $0.91 $0.77 $1.16 $0.71 $1.22
Adjusted Weighted Average Diluted Shares Outstanding
210M 209.70M 206.20M 206.40M 203M 203.90M 199.70M 198.30M 198.80M 198.70M 195.80M
Adjusted Basic & Diluted Earnings per Share
$0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding
208.98M 205.08M 205.73M 203.65M 199.07M 199.06M 197.85M 198.10M 198.18M 195.65M 193.46M
Normalized Net Operating Profit after Tax (NOPAT)
216 291 314 316 218 341 262 217 309 183 300
Normalized NOPAT Margin
12.32% 15.00% 16.60% 16.27% 11.96% 16.83% 13.70% 10.44% 15.42% 8.14% 14.38%
Pre Tax Income Margin
12.50% 14.66% 11.39% 15.56% 12.62% 14.28% 12.00% 10.81% 13.95% 4.37% 14.44%
Debt Service Ratios
- - - - - - - - - - -
EBIT to Interest Expense
5.29 6.65 5.24 6.91 5.24 5.67 4.46 3.83 4.70 2.36 5.38
NOPAT to Interest Expense
3.87 10.39 4.21 5.53 5.57 5.22 3.52 2.58 3.86 3.03 4.29
EBIT Less CapEx to Interest Expense
3.64 5.40 4.16 5.88 4.42 4.84 3.79 3.20 3.97 1.32 4.85
NOPAT Less CapEx to Interest Expense
2.23 9.14 3.13 4.50 4.75 4.39 2.85 1.95 3.13 1.99 3.76
Payout Ratios
- - - - - - - - - - -
Dividend Payout Ratio
43.23% 19.62% 20.90% 20.35% 18.73% 21.69% 21.12% 23.38% 22.60% 26.99% 24.88%
Augmented Payout Ratio
129.30% 87.22% 76.73% 81.50% 130.04% 117.73% 128.87% 133.35% 61.00% 96.06% 91.53%

Financials Breakdown Chart

Key Financial Trends

Zimmer Biomet Holdings, Inc. (NYSE: ZBH) has provided four-year quarterly data. Here is a concise, trend-focused snapshot for retail investors, highlighting the most relevant developments across the last four years. Items are grouped to show positives first, then neutral, and finally potential negatives.

  • Operating revenue has trended higher over 2023–2025, rising from about $1.94B in Q4 2023 to about $2.24B in Q4 2025, reflecting a multi-year topline expansion.
  • Operating cash flow remains robust, with Q4 2025 net cash from continuing operating activities at $517.4M (up from $418.7M in Q3 2025 and about $506.2M in Q4 2024), supporting dividends and buybacks.
  • The balance sheet shows a solid equity base versus liabilities: Total equity around $12.76B and total liabilities around $10.72B in Q3 2025, indicating a conservative capital structure and financial flexibility.
  • Capital allocation includes a quarterly dividend of $0.24 per share and a notable stock repurchase of $250M in Q4 2025, signaling shareholder-friendly activity.
  • Total assets have grown from about $21.2B in 2023 to about $23.5B by 2025, driven by higher noncurrent assets and ongoing investments.
  • R&D intensity remains steady, with quarterly RD expense around $110–$119M, roughly 5% of revenue, supporting ongoing product development.
  • Gross margin shows some variability (e.g., roughly 72% in Q3 2025 versus about 65% in Q4 2025), suggesting near-term margin pressure to monitor.
  • Investing cash flow is typically negative, reflecting capex and acquisitions (for example, net cash from investing activities was about -$322M in Q4 2025), which could pressure near-term cash flow if growth programs accelerate.
  • Asset base includes sizable goodwill and intangible assets (Goodwill around $9.70B and Intangible Assets around $4.74–$4.95B in 2025), creating potential impairment risk if market conditions deteriorate or orthopaedic demand weakens.
05/21/26 05:07 PM ETAI Generated. May Contain Errors.

Zimmer Biomet Financials - Frequently Asked Questions

According to the most recent income statement we have on file, Zimmer Biomet's financial year ends in December. Their financial year 2025 ended on December 31, 2025.

Zimmer Biomet's net income appears to be on an upward trend, with a most recent value of $705.10 million in 2025, rising from $146.20 million in 2015. The previous period was $903.80 million in 2024. View Zimmer Biomet's forecast to see where analysts expect Zimmer Biomet to go next.

Zimmer Biomet's total operating income in 2025 was $1.10 billion, based on the following breakdown:
  • Total Gross Profit: $5.74 billion
  • Total Operating Expenses: $4.64 billion

Over the last 10 years, Zimmer Biomet's total revenue changed from $6.00 billion in 2015 to $8.23 billion in 2025, a change of 37.2%.

Zimmer Biomet's total liabilities were at $10.39 billion at the end of 2025, a 16.8% increase from 2024, and a 39.9% decrease since 2015.

In the past 10 years, Zimmer Biomet's cash and equivalents has ranged from $375.70 million in 2022 to $1.46 billion in 2015, and is currently $591.90 million as of their latest financial filing in 2025.

Over the last 10 years, Zimmer Biomet's book value per share changed from 48.52 in 2015 to 64.07 in 2025, a change of 32.0%.



Financial statements for NYSE:ZBH last updated on 5/2/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.
From Our Partners